How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.
Because of the pressure of significant attrition in drug development, demonstration of target engagement after drug administration enables dose and regimen optimization, patient selection, and stratification from the earliest stages of drug development. The determination of receptor occupancy (RO) can support these efforts. Flow cytometry is one of the preferred technologies to be used based on the important advances in the technology over the last years enabling the simultaneous determination on target cells, of multi intra or surface cell parameters with adequate precision in a regulated environment. Nevertheless, compared to other platforms using the same antigen-antibody binding concept, the flow cytometry approach has faced several challenges, not only due to the technology per se and the diversity of receptor occupancy approaches, but also related to the nature of the matrix where the determination is performed. To illustrate these points, three case studies (antibody-drug conjugate and naked antibody) are provided here to highlight the importance of the choice of the right antibody pair to measure both receptor density (RD) and occupancy by the drug on cancer cells in blood and in bone marrow and the possibility to circumvent the lack of a critical reagent with an innovative approach. In addition, the use of RO data to determine the minimum anticipated biological effect level (MABEL) with translational data from preclinical to human studies, selection of starting dose for the first in man study will be discussed.
Biomarkers Department, BioCytex, Marseille, France.
Maxime
M
Moulard
Sanofi-Aventis Recherche et Développement, DSAR, Head of Biomarkers and Biological Analyses, Vitry-sur-Seine, France.
Marie-Laure
ML
Ozoux
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D055808:Drug Discovery; D005434:Flow Cytometry; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000276:immunology; D022423:Myeloid Cells / Q000187:drug effects / Q000276:immunology; D010950:Plasma Cells / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D007136:Immunoglobulins
AML; B cells; CLL; clinical trial; flow cytometry; immune monitoring; leukemia; oncology; quantification; standardization